إسرائيل - العربية - Ministry of Health

teva pharmaceutical indust.ltd - bicalutamide 150 mg - tablets - bicalutamide - in patients with locally advanced prostate cancer (t3-t4 any n m0 t1-t2 n+ m0) bicalutamide is indicated as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. the management of patients with locally advanced non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable.

إسرائيل - العربية - Ministry of Health

teva pharmaceutical indust.ltd - bicalutamide 50 mg - tablets - bicalutamide - for the treatment of advanced prostate cancer in combination with lhrh analog therapy or surgical castration.

إسرائيل - العربية - Ministry of Health

teva pharmaceutical indust.ltd - alfacalcidol 0.25 mcg - capsules soft gelatin - alfacalcidol - renal bone disease (renal osteodystrophy), hypoparathyroidism, hyperparathyroidism (with bone disease) - primary and tertiary. neonatal hypocalcemia, rickets and osteomalacia, osteoporosis.

إسرائيل - العربية - Ministry of Health

teva pharmaceutical indust.ltd - alfacalcidol 1 mcg - capsules soft gelatin - alfacalcidol - renal bone disease (renal osteodystrophy), hypoparathyroidism, hyperparathyroidism (with bone disease) - primary and tertiary. neonatal hypocalcemia, rickets and osteomalacia, osteoporosis.

إسرائيل - العربية - Ministry of Health

teva pharmaceutical indust.ltd - paracetamol 250 mg / 5 ml - syrup - paracetamol - analgesic, antipyretic.

إسرائيل - العربية - Ministry of Health

amgen europe b.v. - cinacalcet hydrochloride 30 mg - film coated tablets - cinacalcet - treatment of secondary hyperparathyrodism (hpt) in patients with end-dtage renal disease (esrd) on maintenance dialysis therapy. mimpara may be used as part of a therapeutic regimen including phosphate binders and/or vitamin d sterols, as appropriate. reduction of hypercalcaemia in patients with parathyroid carcinoma.

إسرائيل - العربية - Ministry of Health

amgen europe b.v. - cinacalcet hydrochloride 60 mg - film coated tablets - cinacalcet - treatment of secondary hyperparathyrodism (hpt) in patients with end-dtage renal disease (esrd) on maintenance dialysis therapy. mimpara may be used as part of a therapeutic regimen including phosphate binders and/or vitamin d sterols, as appropriate. reduction of hypercalcaemia in patients with parathyroid carcinoma.

إسرائيل - العربية - Ministry of Health

amgen europe b.v. - cinacalcet hydrochloride 90 mg - film coated tablets - cinacalcet - treatment of secondary hyperparathyrodism (hpt) in patients with end-dtage renal disease (esrd) on maintenance dialysis therapy. mimpara may be used as part of a therapeutic regimen including phosphate binders and/or vitamin d sterols as appropriate. reduction of hypercalcaemia in patients with parathyroid carcinoma.

إسرائيل - العربية - Ministry of Health

teva pharmaceutical indust.ltd - topiramate 100 mg - tablets - topiramate - topiramate teva is indicated as adjunctive therapy for adults and children aged 6 and above with partial onset seizures or generalized tonic-clonic seizures. topiramate teva is also indicated in adults and children as adjunctive therapy for the treatment of seizures associated with lennox-gastaut syndrome . topiramate teva is indicated as monotherapy in patients with newly diagnosed epilepsy in adults and children aged 7 years and above or for conversion to monotherapy in patients with epilepsy.topiramate teva is indicated in adults for the prevention of migraines. the use of topiramate teva in the acute treatment of migraine has not been studied .

إسرائيل - العربية - Ministry of Health

teva pharmaceutical indust.ltd - topiramate 200 mg - tablets - topiramate - topiramate teva is indicated as adjunctive therapy for adults and children aged 6 and above with partial onset seizures or generalized tonic-clonic seizures. topiramate teva is also indicated in adults and children as adjunctive therapy for the treatment of seizures associated with lennox-gastaut syndrome . topiramate teva is indicated as monotherapy in patients with newly diagnosed epilepsy in adults and children aged 7 years and above or for conversion to monotherapy in patients with epilepsy.topiramate teva is indicated in adults for the prevention of migraines. the use of topiramate teva in the acute treatment of migraine has not been studied .